| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/15-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| WB Predicted band size | 91 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Rat |
| Immunogen | Synthetic peptide of human PLG |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TIMP1抗体的3篇示例参考文献(内容为虚构概括，仅作示例)：
---
1. **文献名称**：*TIMP1 Expression in Colorectal Cancer: Prognostic Significance and Detection via Novel Monoclonal Antibody*
**作者**：Wang Y, et al.
**摘要**：本研究开发了一种高特异性的抗TIMP1单克隆抗体，用于检测结直肠癌组织中TIMP1的表达水平。通过免疫组化分析发现，TIMP1的高表达与患者总生存期缩短和肿瘤转移风险增加显著相关，提示其作为预后生物标志物的潜力。
2. **文献名称**：*Neutralizing TIMP1 Antibody Attenuates Liver Fibrosis in Murine Models*
**作者**：Smith JL, et al.
**摘要**：研究利用中和性TIMP1抗体干预小鼠肝纤维化模型，发现抗体治疗显著降低胶原沉积和肝星状细胞活化。结果表明，靶向TIMP1可能通过调节MMP/TIMP平衡为抗纤维化治疗提供新策略。
3. **文献名称**：*TIMP1 Antibody-Based Inhibition of Cancer Cell Invasion in Triple-Negative Breast Cancer*
**作者**：Lee H, et al.
**摘要**：通过体外和体内实验，研究发现抗TIMP1抗体可阻断肿瘤细胞与微环境的相互作用，抑制MMP9的活性，从而降低三阴性乳腺癌细胞的侵袭和转移能力，为靶向治疗提供实验依据。
---
以上文献示例展示了TIMP1抗体在癌症预后评估、纤维化疾病治疗及肿瘤转移机制中的研究应用。如需真实文献，建议通过PubMed或Google Scholar检索关键词“TIMP1 antibody”、“anti-TIMP1 therapy”等。
TIMP1 (Tissue Inhibitor of Metalloproteinases 1) is a glycoprotein that plays a critical role in regulating extracellular matrix (ECM) homeostasis by inhibiting matrix metalloproteinases (MMPs), particularly MMP-9. As a key member of the TIMP family, TIMP1 balances ECM degradation and synthesis, influencing tissue remodeling, cell proliferation, and apoptosis. Dysregulation of TIMP1 is implicated in pathologies like fibrosis, cancer, and inflammatory diseases, where its overexpression often correlates with disease progression, such as tumor metastasis or liver fibrosis.
TIMP1 antibodies are essential tools for detecting and quantifying TIMP1 in research and clinical settings. These antibodies enable studies of TIMP1 expression patterns in tissues or fluids via techniques like Western blotting, immunohistochemistry (IHC), or ELISA. In cancer research, TIMP1 antibodies help explore its dual role—while it suppresses MMP activity, elevated TIMP1 levels may paradoxically promote tumor survival and angiogenesis. Similarly, in fibrosis studies, TIMP1 antibodies aid in understanding its contribution to ECM accumulation in organs like the liver or lungs.
Clinically, TIMP1 is investigated as a biomarker for disease prognosis or therapeutic targeting. Antibodies against TIMP1 also support drug development by validating inhibitors or neutralizing agents. Despite its complex roles, TIMP1 remains a focal point in unraveling ECM-related mechanisms, making its antibody a vital reagent in both basic and translational research.
×
